Cencora, Inc. (NYSE:COR – Get Free Report) hit a new 52-week high on Monday after JPMorgan Chase & Co. raised their price target on the stock from $289.00 to $301.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Cencora traded as high as $254.49 and last traded at $253.21, with a volume of 257351 shares traded. The stock had previously closed at $248.48.
Several other research analysts have also recently weighed in on the company. UBS Group boosted their price target on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Mizuho assumed coverage on Cencora in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price for the company. Leerink Partners dropped their price target on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. Evercore ISI boosted their price objective on shares of Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Finally, Wells Fargo & Company lowered their price objective on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating on the stock in a research report on Friday, December 13th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $277.00.
Check Out Our Latest Research Report on Cencora
Insider Buying and Selling
Hedge Funds Weigh In On Cencora
Hedge funds have recently bought and sold shares of the company. Lake Street Advisors Group LLC raised its stake in shares of Cencora by 1.3% during the 3rd quarter. Lake Street Advisors Group LLC now owns 3,415 shares of the company’s stock valued at $769,000 after purchasing an additional 43 shares during the period. Venturi Wealth Management LLC grew its holdings in Cencora by 1.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 4,447 shares of the company’s stock valued at $1,001,000 after buying an additional 46 shares in the last quarter. Prime Capital Investment Advisors LLC increased its position in shares of Cencora by 1.2% during the third quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company’s stock valued at $848,000 after buying an additional 46 shares during the period. Shepherd Financial Partners LLC lifted its holdings in shares of Cencora by 0.9% in the fourth quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company’s stock worth $1,223,000 after buying an additional 46 shares in the last quarter. Finally, J.W. Cole Advisors Inc. boosted its position in shares of Cencora by 1.3% in the third quarter. J.W. Cole Advisors Inc. now owns 3,669 shares of the company’s stock valued at $826,000 after acquiring an additional 48 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.
Cencora Trading Up 0.2 %
The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The company has a market cap of $49.36 billion, a PE ratio of 34.00, a PEG ratio of 1.54 and a beta of 0.49. The firm’s 50 day moving average is $238.03 and its 200 day moving average is $235.30.
Cencora Increases Dividend
The company also recently declared a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date was Friday, November 15th. This is a positive change from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio (DPR) is 29.29%.
Cencora Company Profile
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Read More
- Five stocks we like better than Cencora
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- What is Insider Trading? What You Can Learn from Insider Trading
- What Does the Future Hold for Eli Lilly?
- Canada Bond Market Holiday: How to Invest and Trade
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.